In This Section      
Home > Heart & Vascular Institute > Cardiology > Ciccarone Center > Collections > Authors
 

Steven Jones, MD

Ciccarone Center Research

Published By

Steven Jones, MD

Steven Jones, MD
Jones, Steven, MD

Steven Jones, MD is the Director of Inpatient Cardiology and is part of the faculty at the Ciccarone Center for the Prevention of Heart Disease, The Longscope Firm, and Osler Medical Service. Additionally, he is an Assistant Professor of Medicine.

View my Johns Hopkins Medicine profile for more information and to request an appointment.

Landmark Articles

  • Risk and the physics of clinical prediction.
    This study shifts the focus from prediction of events to detection of disease in the effort to improve personalized decision-making and outcomes. It also discusses innovative future strategies for risk estimation and treatment allocation in preventive cardiology.
    Published in: American Journal of Cardiology
    Read on Pubmed
  • Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.
    CAC scoring can help match statin therapy to absolute atherosclerotic CVD risk.
    Published in: Circulation
    Read on Pubmed
  • Low-risk lifestyle, coronary calcium, cardiovascular events, and mortality: Results from MESA.
    Unhealthy lifestyle habits are a major contributor to coronary artery disease (CAD). The purpose of the study was to investigate the associations of smoking, weight maintenance, physical activity, and Mediterranean-style diet with coronary calcium, cardiovascular events, and mortality. We discovered that, over the course of nearly 8 years, a combination of regular exercise, healthy diet, smoking avoidance, and weight maintenance contributed to lower coronary calcium incidence, slower calcium progression, and lower all-cause mortality.
    Published in: American Journal of Epidemiology
    Read on Pubmed
  • A point-by-point response to recent arguments against the use of statins in primary prevention.
    Early in 2012, a debate over the merits of statin therapy in primary prevention was published in the Wall Street Journal. The statin opponent claimed that statins should only be used in secondary prevention and never in any primary-prevention patients at risk for cardiovascular events. In this evidence-based rebuttal to those claims, we review the evidence supporting the efficacy of statin therapy in primary prevention. Cardiovascular risk is a continuum in which those at an elevated risk of events stand to benefit from early initiation of therapy. Statins should not be reserved until after a patient suffers the catastrophic consequences of atherosclerosis. Contrary to the assertions of the statin opponent, this principle has been demonstrated through reductions in heart attacks, strokes, and mortality in numerous randomized controlled primary-prevention statin trials. In selected at-risk individuals, the combination of pharmacotherapy and lifestyle changes is more effective than either alone. Future investigation in prevention should focus on improving our ability to identify these at-risk individuals.
    Published in: Clinical Cardiology
    Read on Pubmed
  • Coronary artery calcium progression: an important clinical measurement? A review of published reports.
    Baseline CAC accurately identifies coronary atherosclerosis and improves prediction of future cardiac events. However, whether knowledge of progression of CAC scores over time further improves risk prediction is unclear. We conducted a comprehensive review of published reports on CAC progression and found that CAC progression correlates with worsening atherosclerosis and may facilitate prediction of future cardiac events. These findings support the notion that slowing CAC progression with therapeutic interventions might provide prognostic benefit. However, despite promising early data, such interventions (most notably with statin therapy) have not been shown to slow the progression of CAC in any randomized controlled trial to date, outside of post hoc subgroup analyses. Thus, routine quantification of CAC progression cannot currently be recommended in clinical practice.
    Published in: Journal of the American College of Cardiology
    Read on Pubmed

Response to letter by Dr. Lin regarding article, “HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative.

By: Martin SS, Li Y, Spertus JA, Jones SR.

Novel biomarkers and risk factors.

By: Cheng HG, Martin SS, Jones SR.

Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring cohort studies.

By: Joshi PH, Toth PP, Lirette ST, Griswold ME, Massaro JM, Martin SS, Blaha MJ, Kulkarni KR, Khokhar AA, Correa A, D’Agostino Sr RB, Jones SR, on behalf of the Lipoprotein Investigators Collaborative (LIC) Study Group.
This study found that smaller, denser HDL3-C levels are primarily responsible for the inverse association between HDL-C and incident CHD in this diverse group of primary prevention subjects.
Read on Pubmed

High-density lipoprotein subfractions: current views and clinical practice applications.

By: Martin SS, Jones SR, Toth PP.
This report prioritizes higher-resolution HDL measurement techniques that capture better the biologically and clinically important characteristics of HDL.
Read on Pubmed

Metabolomic analysis of pressure-overloaded and infarcted mouse hearts.

By: Sansbury BE, De Martino AM, Xie Z, Brooks AC, Brainard RE, Watson LJ, DeFilippis AP, Cummins TD, Harbeson MA, Brittian KR, Prabhu SD, Bhatnagar A, Jones SP, Hill BG.
These findings reveal extensive metabolic remodeling common to both hypertrophic and failing hearts that are indicative of extracellular matrix remodeling, insulin resistance and perturbations in amino acid, and lipid and nucleotide metabolism.
Read on Pubmed

HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: The Lipoprotein Investigators Collaborative.

By: Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, Toth PP, Muhlestein JB, Anderson JL, Knight S, Li Y, Spertus JA, Jones SR; on behalf of the Lipoprotein Investigators Collaborative (LIC).
In secondary prevention, increased risk for long-term hard clinical events is associated with low HDL3-C, but not HDL2-C or HDL-C, highlighting the potential value of subclassifying HDL-C.
Read on Pubmed

2013 American cholesterol treatment guideline: what was done well and what could be done better.

By: Martin SS, Abd TT, Jones SR, Michos ED, Blumenthal RS, Blaha MJ.
This article critically appraises the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol. The guideline succeeds in prioritizing statin therapy, expanding focus to atherosclerotic cardiovascular disease including stroke, and in emphasizing absolute cardiovascular risk to determine statin eligibility.
Read on Pubmed

Letter by Jones et al regarding article, “Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.”

By: Jones SR, Martin SS, Brinton EA.
Read on Pubmed

Usefulness of coronary and carotid imaging rather than traditional atherosclerotic risk factors to identify firefighters at increased risk for cardiovascular disease.

By: Ratchford EV, Carson KA, Jones SR, Ashen MD.
Early detection and integration of imaging with traditional risk assessment will be important in preventing premature death and disability among firefighters.
Read on Pubmed

Narrowing sex differences in lipoprotein cholesterol subclasses following mid-life: the very large database of lipids (VLDL-10B).

By: Swiger KJ, Martin SS, Blaha MJ, Toth PP, Nasir K, Michos ED, Gerstenblith G, Blumenthal RS, Jones SR.
The narrowing sex differential in CVD risk after midlife is mirrored by a higher total atherogenic lipoprotein cholesterol burden in women and a closer approximation of the less favorable density phenotype characteristic of men.
Read on Pubmed

Request an Appointment

Maryland Patients

Cardiology: 443-997-0270
Cardiac Surgery: 410-955-2800
Vascular: 410-955-5165

Already a Patient?

Request your next appointment through MyChart!

   
 

Traveling for Care?

Whether you're crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Outside of Maryland (toll free)
410-464-6713
Request an Appointment
Medical Concierge Services

International Patients
+1-410-502-7683
Request an Appointment
Medical Concierge Services

 
blue suitcase
Show me more...
I want to...
Health Library
Female African-American doctor smiling

Explore our health library for more information about conditions and treatments.

Physicians in Your Community
physician in hospital setting

Find a comprehensive range of specialists at convenient locations throughout Maryland.

Locations
The Johns Hopkins Hospital

The Sheikh Zayed Tower brings the best of patient-centered medicine to the Heart and Vascular Institute.